A Multicenter, Open Label, Phase 1 Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INC280 Tablet Formulation With Food in Patients With cMET Dysregulated Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Capmatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 12 Sep 2017 Planned End Date changed from 16 Apr 2018 to 18 Dec 2017.
- 12 Sep 2017 Planned primary completion date changed from 30 Nov 2018 to 6 Nov 2017.
- 06 Jun 2017 Planned primary completion date changed from 16 Apr 2018 to 30 Nov 2018.